{"id":"W4389487695","doi":"10.1016/j.iotech.2023.100587","title":"115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"Genentech; LEO Pharma; Aptitude Health; European Society for Medical Oncology; Novocure; Regeneron Pharmaceuticals; Gilead Sciences; Ipsen; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Neoadjuvant therapy; Internal medicine; Durvalumab; Oncology; Stage (stratigraphy); Chemotherapy; Radiology; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001076866,0.001093356,0.001458701,0.0002416092,0.0002978801,0.0009068616,0.0008899892,0.001143244,0.005949538],"category_scores_gemma":[0.0007055253,0.0004299693,0.001204845,0.0003096747,0.0005743215,0.0006330829,0.0003763357,0.003061536,0.001515495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008231794,"about_ca_system_score_gemma":0.001336635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001082337,"about_ca_topic_score_gemma":0.003322117,"domain_scores_codex":[0.9997726,0.0001038424,0.00001381986,0.00003820693,0.00002846907,0.00004306423],"domain_scores_gemma":[0.9996107,0.00006229506,0.00006416155,0.00003077013,0.0000271414,0.000204973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6750806,0.07992527,0.007340947,0.00262788,0.002647218,0.0002475338,0.0003502402,0.002449418,0.0535505,0.0007824117,0.01244877,0.1625492],"study_design_scores_gemma":[0.6888365,0.2920952,0.00894609,0.00008653342,0.0005804518,0.0001973136,0.00006247302,0.0009713709,0.002565845,0.0002261469,0.005400292,0.00003170048],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775698,0.003707032,0.0009319441,0.001061597,0.0003879824,0.005877826,0.003876716,0.0002311879,0.006355882],"genre_scores_gemma":[0.9623253,0.004488101,0.004147479,0.003390411,0.0002900248,0.00700835,0.009732023,0.00007699739,0.008541374],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005949538,"threshold_uncertainty_score":0.01990312,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02619642708077443,"score_gpt":0.3546546211225938,"score_spread":0.3284581940418194,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}